NCT01175980 · OUTCOME

Objective Response According to RECIST 1.1 Criteria

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma · Source last updated 2020-08-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months

What was measured

Objective (Best) response according to RECIST 1.1 criteria.

Groups in this outcome

Treatment (Vorinostat)

Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Vorinostat)	30

Reported measurements

Source class 1

Partial Response

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Vorinostat)	2	Not reported	Not reported	Not reported	Not reported

Stable Disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Vorinostat)	27	Not reported	Not reported	Not reported	Not reported

Progressive Disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Vorinostat)	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2
title
Partial Response
measurements
group Id
OG000
value
27
title
Stable Disease
measurements
group Id
OG000
value
1
title
Progressive Disease

denoms

counts
group Id
OG000
value
30
units
Participants

description

Objective (Best) response according to RECIST 1.1 criteria.

groups

description
Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Vorinostat: Given PO
id
OG000
title
Treatment (Vorinostat)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months

title

Objective Response According to RECIST 1.1 Criteria

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice